Coursera Stock Forum

$Coursera (COUR.US)$ I was up in the middle of night reading a Morgan Stanley report. in this reported outlined several potential problems with artificial intelligence going forward. the top problem that they said that could create a limitation a bottleneck is the lack of professionals in this space the lack of training that exists to provide individuals that have the experience needed to the companies that are not only established but just starting out.
I started doing some reading and then Lin...

$3M (MMM.US)$
— Shares surged more than 18% to hit a 52-week high after the maker of office supplies and adhesives reported stronger-than-expected quarterly results. 3M posted second-quarter adjusted earnings of $1.93 per share, exceeding an LSEG estimate of $1.68 per share. Revenue also topped Wall Street’s forecast.
$DexCom (DXCM.US)$
— Shares plummeted more than 40% after the medical device maker missed expe...

$Coursera (COUR.US)$ will it fall today

Good afternoon, traders. It's finally Friday, July 26; the market is open, and prices are taking back some losses felt in a pullback midweek.
My name is Kevin Travers, here are stories from the herd on Wall St today.
$3M (MMM.US)$ lifted the low end of its full-year earnings outlook on Friday after reporting second-quarter results above market estimates, it flew 19%, yanking the Dow higher as the highest advancer.
$DexCom (DXCM.US)$ fell 41%,...

$Coursera (COUR.US)$ tq for 2 times

$Coursera (COUR.US)$ jumped 44% Friday after reporting a Q2 loss Thursday night that came in lower than the previous quarter. The AI tech education company posted 155 million total users, revenue of $170M, and GAAP earnings of $0.15, but adjusted earnings of $0.09/share.
Friday morning, the firm enjoyed a maintained 'sell' opinion from an analyst at Goldman Sachs.
Still, the firm announced Q2 results that beat estimates and celebrated 2 mill...

$Coursera (COUR.US)$ dropping .

$Coursera (COUR.US)$ will it dip after opening

$DexCom (DXCM.US)$ — Shares of the medical device company plunged more than 35%. Dexcom’s fiscal full-year revenue guidance of $4 billion to $4.05 billion marked a reduction from the outlook it shared earlier in the year. Revenue in the second quarter missed analysts’ expectations, coming in at $1 billion versus consensus estimates of $1.04 billion, per LSEG. Insulet shares slipped 9.1% in sympathy.
$Boston Beer (SAM.US)$ –...